What is MDMA?

MDMA is a synthetic psychoactive substance, also called midomafetamine. It alters serotonin, norepinephrine, and dopamine signaling. It is often described as an entactogen, a term associated with emotional openness and connection, and has stimulant effects. Its pharmacology differs from classic psychedelics such as psilocybin. [1]

In MDMA-assisted therapy research, the question is whether its temporary effects can help a person engage in psychological work. The drug session and the lasting outcome are related questions, but they are not interchangeable.


What can it feel like?

For me, the most striking qualities were warmth, clarity, and a sense of being able to stay present. That is one account. Someone else may feel stimulated, uncomfortable, frightened, emotionally flooded, or less changed than they expected.

A moving experience also does not tell you in advance what the following days will be like. My good experience is not evidence that a difficult comedown cannot happen, or that one must be caused by partying. I want the range of possibilities to remain visible.

A clinical description can name effects. Personal writing can offer texture. Neither can forecast your experience.


How did it become a possible therapy?

MDMA appears in Merck’s 1912 records as a chemical intermediate. Researchers who examined the original archives challenged the often-repeated claim that it was invented as an appetite suppressant. [2]

By the 1980s, its potential uses and its legal classification were being argued in public. The 1987 Grinspoon court decision records disagreement among clinicians, the DEA, and an administrative law judge about the evidence and the standards used to schedule it. [3]

That history helps explain why MDMA arrives with such different associations: a recreational drug, a proposed therapeutic aid, and a controlled substance. Each description carries part of the story.

What did the PTSD trials find?

Post-traumatic stress disorder, or PTSD, can include intrusive memories, avoidance, changes in mood and beliefs, and a persistent sense of threat. The key trials studied people who met diagnostic criteria. They were not tests of general wellbeing or every experience described as trauma.

In the 2021 phase 3 trial, 90 adults with severe PTSD were randomized. At the 18-week endpoint, 28 of 42 assessed participants receiving MDMA plus therapy no longer met PTSD criteria, compared with 12 of 37 receiving placebo plus therapy: 67% versus 32%. [4]

The 2023 confirmatory trial randomized 104 adults with moderate-to-severe PTSD. Loss of diagnosis at 18 weeks was reported for 37 of 52 assessed MDMA participants and 20 of 42 placebo participants: 71.2% versus 47.6%. Both groups received the same therapy program. [5]

These percentages concern a diagnostic threshold at a particular follow-up. They are not lifetime cure rates. The assessed denominators are smaller than the randomized groups, and the placebo group also improved substantially.

The practical reason to pay attention is the possibility of meaningful change in a serious condition. The practical reason to read carefully is that a headline percentage cannot tell an individual what will happen to them.

Why did the studies use several sessions?

The phase 3 treatment program included three preparation visits, three day-long drug or placebo sessions approximately a month apart, and nine integration visits. Participants were screened and monitored. [4]

The 2023 authors reported that the groups did not separate after the first experimental session; the clearer difference emerged over the treatment course. [5]

That supports taking cumulative treatment seriously. It does not establish that everybody needs exactly three MDMA sessions, or that a first session cannot be meaningful. Participants were not randomized to stop after one session versus continue for three. Time, further therapy, repeated exposure, and changes in dosing also complicate attributing improvement to session count alone.

The reasonable takeaway is to avoid expecting one experience to reproduce the outcome of an entire research program. Deciding whether another session is appropriate requires individual assessment, not a number borrowed from a headline.


How is that different from single-dose psilocybin research?

A 2023 trial randomized 104 adults with major depressive disorder to one psilocybin session or niacin placebo, with psychological support. Depression scores improved more with psilocybin across six weeks. Adverse events were more frequent in the psilocybin group. [6]

That is evidence that one supported psilocybin session can have effects beyond the dosing day for some people. It is not a head-to-head comparison with MDMA. The conditions, drugs, populations, and treatment programs differ. We cannot conclude from these separate trials that psilocybin always needs one session while MDMA always needs several.

What makes the evidence harder to interpret?

Participants can often recognize a strong psychoactive effect, making effective blinding difficult. Expectation, the therapeutic relationship, and the treatment setting may influence outcomes. The FDA’s 2024 response raised specific concerns about safety reporting, selection and expectancy bias, and evidence for benefit beyond the short-term endpoint. [7]

Some older evidence also requires a correction. The 2019 pooled phase 2 analysis was retracted in 2024. The editors cited undisclosed protocol violations amounting to unethical conduct at one study site and incomplete competing-interest disclosures. Several authors disagreed with the retraction. This guide does not use that paper as current evidence of efficacy or an optimal session count. [8]

That retraction concerns a different paper from the two phase 3 trials described above. It is a reason to inspect the research record, not to blur all studies together.

Similarly, results in PTSD cannot simply be relabeled as established evidence for complex PTSD as a separate diagnosis, depression, relationship distress, addiction, or chronic pain. Each question deserves its own studies.

What are the risks?

MDMA can raise blood pressure, heart rate, and temperature. Serious risks include overheating, low blood sodium, and serotonin toxicity. Health conditions, medications, other substances, and the environment can affect risk. These concerns are not eliminated by describing an experience as therapeutic. [1]

In the 2023 trial, severe treatment-emergent events occurred in 5 of 53 MDMA participants and 2 of 51 placebo participants. No serious treatment-emergent events were reported. Common reported effects included muscle tightness, nausea, decreased appetite, and sweating. [5]

In research reporting, “severe” describes intensity; “serious” refers to outcomes such as hospitalization or danger to life. Those terms should not be substituted for one another. A small trial also cannot reliably detect every uncommon harm. [9]

Medication decisions and medical screening belong with a qualified clinician. Do not stop prescribed medication on the basis of this guide. Psychological and relational safety matter too: consent, boundaries, the ability to stop an intervention, and access to appropriate care if someone becomes distressed.

The intensity of an altered state can make a person vulnerable to suggestion and misconduct. A reassuring manner or a beautiful setting is not a substitute for accountable practice.

Is MDMA FDA-approved?

United States status reviewed October 22, 2026: MDMA is not FDA-approved for clinical use, according to the VA National Center for PTSD’s current overview. [10]

The FDA declined the 2024 application and identified additional evidence it needed. In August 2026, MAPS responded to a report that the developer had resubmitted its application. MAPS explicitly stated that it had no active role in that development program. A reported resubmission is not approval. [7] [11]

The broader policy landscape is changing. FDA finalized psychedelic-trial guidance in July 2026 and is supporting further drug development. Research designations, policy announcements, and clinical approval are different steps. Check the linked sources again before making decisions, because this section is time-sensitive. [12] [13]


What the firsthand accounts add

One account collected in Alexander and Ann Shulgin’s PiHKAL describes being able to “talk about deep or personal subjects with special clarity.” The same entry includes a distinctly unhappy account. Reading them together makes the range of experiences harder to flatten into a single story. [14]

Anne Other’s Trust Surrender Receive adds a collection of personal accounts that gave me more language for the emotional possibilities of MDMA. I read these alongside research, with different questions in mind: what can an experience feel like, and what can a study actually establish?

What do preparation and integration actually involve?

Preparation can include understanding why an experience appeals to you, what you hope might change, what feels frightening, and what questions to bring to qualified clinicians or providers. It also involves thinking about support, responsibilities, consent, and what you will do if the experience differs from what you hoped.

Integration is the process of relating what happened to your life afterward. That could mean finding words for an experience, noticing emotional or bodily responses, reconsidering a belief, or working out how to have a conversation you have been avoiding. It can also mean acknowledging that an experience was confusing or unhelpful.

A feeling of certainty does not require an immediate decision. An interpretation can remain provisional while you see how it holds up in ordinary life. You get to decide what is meaningful to you.

The trials included substantial support. They did not isolate the independent effect of integration or prove that one specific integration approach is best. I value support because it creates room for attention, reflection, and accountability, without requiring a particular story of transformation.


The questions worth bringing with you

What exactly am I hoping will change? What have I already tried, and what has helped? What does the evidence say about my actual concern? Who is qualified to assess medical and psychiatric suitability? What are this provider’s scope, boundaries, and plans if something goes wrong? What support will be available afterward?

You can investigate all of this before deciding whether an altered-state experience belongs in your life. Learning to trust your questions is part of the work.

Sources & further reading

1. FDA’s 2024 MDMA review and safety assessment

2. Merck archive study of MDMA’s origins, 2006

3. Grinspoon v. DEA, original 1987 court opinion

4. Mitchell and colleagues: MDMA PTSD trial, 2021

5. Mitchell and colleagues: MDMA PTSD trial, 2023

6. Raison and colleagues: single-dose psilocybin for depression, 2023

7. FDA’s August 2024 complete response letter

8. Retraction notice for the 2019 pooled phase 2 MDMA analysis

9. FDA clinical safety definitions: severe versus serious

10. VA National Center for PTSD: MDMA-assisted therapy

11. MAPS statement on a reported resubmission, August 2026

12. FDA psychedelic-drug development updates

13. FDA final clinical-investigation guidance, July 2026

14. Alexander and Ann Shulgin: PiHKAL, entry 109, qualitative comments


Keep exploring

Beyond the Myths
The sunset, the inherited warnings, and the experience that sent me back to the evidence.

Noticing the Window
What it can mean when old patterns return after a meaningful experience.